‘We see inconsistent messages, actions, investments and strategies regarding importance of the doctor of new technologies, and if not treated, this looming provider disconnect will certainly limit the effectiveness of the U.S. P4P initiatives. ‘. To view the full press release.. Heart failure is the cause of more than one million hospitalizations each year and costs the health care system in the United States more than $ 29 billion per year.Survey of Healthcare Payers revealed major setback with Pay for Performance programs, United Statesconducted a recent survey by Health Industry Insights, an IDC company, results show an important between payers ‘ separate Pay for Performance program objectives and provider incentives and technology investment.
Nearly five million Americans suffer from heart failure, a condition in which the weakened heart and the blood is not pumping efficiently. Some 200,000 of these patients needed badly to drugs and often hospitalization. Coronary artery disease, previous heart attack, cardiomyopathy, and other cardiovascular diseases can cause heart failure. Symptoms of the disease include shortness of breath, wheezing and edema.The HGS clinical development pipeline includes novel medicines for hepatitis C, anthrax conditions, treat cancer and other autoimmune diseases. The company main focus is speedy progress in the direction the marketing of their two significant of lead drugs, promote Albuferon on hepatitis C LymphoStat – B. for Systemic Lupus. Phase 3 clinical trials both medications are ongoing.
Reaction to recent reports of which indicates a link between long-term bisphosphonate use and rarely broken bones mentioned subtrochanteric femoral shaft, issued The Endocrine Society a statement indicating that it moment is no conclusive evidence that bisphosphonates causing of this rare type of fracture. – Although a number of messages indicating a potential link between long -term use of biphosphonate medication for an unusual type of fracture, it emphasize to stress lot studies have the efficacy of these drugs, confirming in the reduction of risk of bone fracture in patients with osteoporosis, said Robert A.